Trial Profile
Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy; Eye disorders; Myopia; Retinal disorders; Wet age-related macular degeneration
- Focus Therapeutic Use
- 27 Aug 2018 Planned End Date changed from 1 Sep 2017 to 1 Dec 2019.
- 27 Aug 2018 Planned primary completion date changed from 1 May 2017 to 1 May 2019.
- 01 Oct 2017 Results (n=60) assessing long-term safety and efficacy of ziv-aflibercept in retinal diseases, were published in the British Journal of Ophthalmology.